Summary

PCSK9 Inhibitor Market – Scope of Report
TMR’s report on the global PCSK9 inhibitor market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global PCSK9 inhibitor market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global PCSK9 inhibitor market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the PCSK9 inhibitor market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global PCSK9 inhibitor market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global PCSK9 inhibitor market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global PCSK9 inhibitor market.

The report delves into the competitive landscape of the global PCSK9 inhibitor market. Key players operating in the global PCSK9 inhibitor market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global PCSK9 inhibitor market profiled in this report.

Key Questions Answered in Global PCSK9 inhibitor Market Report
• What is the sales/revenue generated by PCSK9 inhibitor across all regions during the forecast period?
• What are the opportunities in the global PCSK9 inhibitor market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

PCSK9 Inhibitor Market – Research Objectives and Research Approach
The comprehensive report on the global PCSK9 inhibitor market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global PCSK9 inhibitor market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global PCSK9 inhibitor market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global PCSK9 Inhibitors Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global PCSK9 Inhibitors Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global PCSK9 Inhibitors Market Analysis and Forecast, by Drug Type
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Type, 2020-2034
        6.3.1. Alirocumab
        6.3.2. Evolocumab
        6.3.3. Inclisiran
        6.3.4. Tafolecimab
    6.4. Market Attractiveness, by Drug Type
7. Global PCSK9 Inhibitors Market Analysis and Forecast, by Modality
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Modality, 2020-2034
        7.3.1. Fully-humanized Monoclonal Antibodies
        7.3.2. siRNA
    7.4. Market Attractiveness, by Modality
8. Global PCSK9 Inhibitors Market Analysis and Forecast, by Indication
    8.1. Introduction and Definitions
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Indication, 2020-2034
        8.3.1. Primary Hyperlipidemia
        8.3.2. Familial Hyper Cholesterolemia
        8.3.3. Other Cardiovascular Disorders
    8.4. Market Attractiveness, by Indication
9. Global PCSK9 Inhibitors Market Analysis and Forecast, by Distribution Channel
    9.1. Introduction and Definitions
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Distribution Channel, 2020-2034
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Attractiveness, by Distribution Channel
10. Global PCSK9 Inhibitors Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2020-2034
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness, by Region
11. North America PCSK9 Inhibitors Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Type, 2020-2034
        11.2.1. Alirocumab
        11.2.2. Evolocumab
        11.2.3. Inclisiran
        11.2.4. Tafolecimab
    11.3. Market Attractiveness, by Drug Type
    11.4. Market Value Forecast, by Modality, 2020-2034
        11.4.1. Fully-humanized Monoclonal Antibodies
        11.4.2. siRNA
    11.5. Market Attractiveness, by Modality
    11.6. Market Value Forecast, by Indication, 2020-2034
        11.6.1. Primary Hyperlipidemia
        11.6.2. Familial Hyper Cholesterolemia
        11.6.3. Other Cardiovascular Disorders
    11.7. Market Attractiveness, by Indication
    11.8. Market Value Forecast, by Distribution Channel, 2020-2034
        11.8.1. Hospital Pharmacies
        11.8.2. Retail Pharmacies
        11.8.3. Online Pharmacies
    11.9. Market Attractiveness, by Distribution Channel
    11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        11.10.1. U.S.
        11.10.2. Canada
    11.11. Market Attractiveness Analysis
        11.11.1. By Drug Type
        11.11.2. By Modality
        11.11.3. By Indication
        11.11.4. By Distribution Channel
        11.11.5. By Country
12. Europe PCSK9 Inhibitors Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Type, 2020-2034
        12.2.1. Alirocumab
        12.2.2. Evolocumab
        12.2.3. Inclisiran
        12.2.4. Tafolecimab
    12.3. Market Attractiveness, by Drug Type
    12.4. Market Value Forecast, by Modality, 2020-2034
        12.4.1. Fully-humanized Monoclonal Antibodies
        12.4.2. siRNA
    12.5. Market Attractiveness, by Modality
    12.6. Market Value Forecast, by Indication, 2020-2034
        12.6.1. Primary Hyperlipidemia
        12.6.2. Familial Hyper Cholesterolemia
        12.6.3. Other Cardiovascular Disorders
    12.7. Market Attractiveness, by Indication
    12.8. Market Value Forecast, by Distribution Channel, 2020-2034
        12.8.1. Hospital Pharmacies
        12.8.2. Retail Pharmacies
        12.8.3. Online Pharmacies
    12.9. Market Attractiveness, by Distribution Channel
    12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        12.10.1. Germany
        12.10.2. U.K.
        12.10.3. France
        12.10.4. Italy
        12.10.5. Spain
        12.10.6. Rest of Europe
    12.11. Market Attractiveness Analysis
        12.11.1. By Drug Type
        12.11.2. By Modality
        12.11.3. By Indication
        12.11.4. By Distribution Channel
        12.11.5. By Country/Sub-region
13. Asia Pacific PCSK9 Inhibitors Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Type, 2020-2034
        13.2.1. Alirocumab
        13.2.2. Evolocumab
        13.2.3. Inclisiran
        13.2.4. Tafolecimab
    13.3. Market Attractiveness, by Drug Type
    13.4. Market Value Forecast, by Modality, 2020-2034
        13.4.1. Fully-humanized Monoclonal Antibodies
        13.4.2. siRNA
    13.5. Market Attractiveness, by Modality
    13.6. Market Value Forecast, by Indication, 2020-2034
        13.6.1. Primary Hyperlipidemia
        13.6.2. Familial Hyper Cholesterolemia
        13.6.3. Other Cardiovascular Disorders
    13.7. Market Attractiveness, by Indication
    13.8. Market Value Forecast, by Distribution Channel, 2020-2034
        13.8.1. Hospital Pharmacies
        13.8.2. Retail Pharmacies
        13.8.3. Online Pharmacies
    13.9. Market Attractiveness, by Distribution Channel
    13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.10.1. China
        13.10.2. Japan
        13.10.3. India
        13.10.4. Australia & New Zealand
        13.10.5. Rest of Asia Pacific
    13.11. Market Attractiveness Analysis
        13.11.1. By Drug Type
        13.11.2. By Modality
        13.11.3. By Indication
        13.11.4. By Distribution Channel
        13.11.5. By Country/Sub-region
14. Latin America PCSK9 Inhibitors Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Type, 2020-2034
        14.2.1. Alirocumab
        14.2.2. Evolocumab
        14.2.3. Inclisiran
        14.2.4. Tafolecimab
    14.3. Market Attractiveness, by Drug Type
    14.4. Market Value Forecast, by Modality, 2020-2034
        14.4.1. Fully-humanized Monoclonal Antibodies
        14.4.2. siRNA
    14.5. Market Attractiveness, by Modality
    14.6. Market Value Forecast, by Indication, 2020-2034
        14.6.1. Primary Hyperlipidemia
        14.6.2. Familial Hyper Cholesterolemia
        14.6.3. Other Cardiovascular Disorders
    14.7. Market Attractiveness, by Indication
    14.8. Market Value Forecast, by Distribution Channel, 2020-2034
        14.8.1. Hospital Pharmacies
        14.8.2. Retail Pharmacies
        14.8.3. Online Pharmacies
    14.9. Market Attractiveness, by Distribution Channel
    14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        14.10.1. Brazil
        14.10.2. Mexico
        14.10.3. Rest of Latin America
    14.11. Market Attractiveness Analysis
        14.11.1. By Drug Type
        14.11.2. By Modality
        14.11.3. By Indication
        14.11.4. By Distribution Channel
        14.11.5. By Country/Sub-region
15. Middle East & Africa PCSK9 Inhibitors Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Drug Type, 2020-2034
        15.2.1. Alirocumab
        15.2.2. Evolocumab
        15.2.3. Inclisiran
        15.2.4. Tafolecimab
    15.3. Market Attractiveness, by Drug Type
    15.4. Market Value Forecast, by Modality, 2020-2034
        15.4.1. Fully-humanized Monoclonal Antibodies
        15.4.2. siRNA
    15.5. Market Attractiveness, by Modality
    15.6. Market Value Forecast, by Indication, 2020-2034
        15.6.1. Primary Hyperlipidemia
        15.6.2. Familial Hyper Cholesterolemia
        15.6.3. Other Cardiovascular Disorders
    15.7. Market Attractiveness, by Indication
    15.8. Market Value Forecast, by Distribution Channel, 2020-2034
        15.8.1. Hospital Pharmacies
        15.8.2. Retail Pharmacies
        15.8.3. Online Pharmacies
    15.9. Market Attractiveness, by Distribution Channel
    15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        15.10.1. GCC Countries
        15.10.2. South Africa
        15.10.3. Rest of Middle East & Africa
    15.11. Market Attractiveness Analysis
        15.11.1. By Drug Type
        15.11.2. By Modality
        15.11.3. By Indication
        15.11.4. By Distribution Channel
        15.11.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2023)
    16.3. Company Profiles
        16.3.1. Novartis AG
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Regeneron Pharmaceuticals
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Amgen Inc.
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Innovent Bio
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. LIB Therapeutics
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Shanghai Junshi Biosciences Co., Ltd.
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Merck & Co., Inc.
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. AstraZeneca plc
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview